Emcure Pharmaceuticals Ltd.EMCURE₹1,439.80 +7.46%

Emcure Pharmaceuticals Ltd. has completed a major deal, spending ₹7,249 Million to buy the remaining 20.42% of its subsidiary, Zuventus Healthcare. This purchase makes Zuventus, a profitable pharmaceuticals company, a 100% owned subsidiary of Emcure. 

In Q1FY26, the company (Emcure Pharmaceuticals) achieved its highest-ever quarterly profit of ₹215 crore, marking a 41% growth year-over-year (YoY). 

Revenue from operations reached ₹2,101 crore (up 15.7% YoY), driven by excellent growth in both the International (22% YoY) and Domestic (9.4% YoY) businesses. Strong operating leverage helped lift EBITDA by 20.1% YoY, achieving an improved margin of 19.2%. 

Looking ahead, Emcure is pursuing a 5-year vision to expand operating margins to 23-24% and is strengthening its market position through strategic partnerships, including an expanded agreement with Sanofi for key oral diabetic brands.

Let’s take a look at its Factor Analysis scores:

Note: The stock prices mentioned are as of 12:20 pm

Disclaimer and Disclosure 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI, enlistment as Research Analyst with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Kindly refer to  https://share.market/ for more details.Investments in WealthBaskets are subject to the Terms of Service. All investors are advised to conduct their own independent research into investment strategies before making an investment decision. PPWB acts as a distributor of mutual funds and it is not an exchange traded product. PPWB acts as a distributor of mutual funds and WealthBaskets and it is not an exchange traded product. Disputes with respect to the distribution activity of Mutual Funds and WealthBaskets will not have access to Exchange investor redressal or Arbitration mechanism. The securities are quoted as an example and not as a recommendation. This is for informational purposes and should not be considered as recommendations.

PhonePe Wealth Broking Private Limited is a member of NSE & BSE with SEBI Regn. No.: INZ000302639, Depository Participant of CDSL Depository with SEBI Regn. No.: IN-DP-696-2022, Research Analyst with SEBI Regn No: INH000013387, BSE RA Enlistment Number: 5887 and Mutual Fund distributor with AMFI Registration No: ARN- 187821. Member ID: BSE- 6756, NSE- 90226. Registered office – 2, Floor 3, Wing A, Block A, Salarpuria Softzone, Service Road, Green Glen Layout, Bellandur, Bengaluru South, Bengaluru, Karnataka – 560103, INDIA. CIN: U65990KA2021PTC146954